Anti-Met (c-Met) antibody (ab14570)
- Product nameAnti-Met (c-Met) antibodySee all Met (c-Met) primary antibodies ...
- DescriptionRabbit polyclonal to Met (c-Met)
- Tested applicationsIP, WB more details
- Species reactivityReacts with: Mouse, Dog
Predicted to work with: Rat
Synthetic peptide: APYPSLLPSQDNIDGEGNT conjugated to Ovalbumin, corresponding to amino acids 1361-1379 of Mouse Met (c-Met). The immunizing sequence has 18 of 19 identical amino acids in rat.
- Positive controlMouse liver membrane fractions.
- Storage instructionsAdd glycerol to a final volume of 50%, aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.05% Sodium Azide
Constituents: 30% Glycerol, 0.15M Sodium Chloride, 0.1M Tris-glycine. pH 7.4
- Concentration information loading...
- PurityProtein A purified
- Primary antibody notes Met (c-Met), a high affinity receptor for hepatocyte growth factor (HGF; also known as scatter factor), is a disulfide-linked heterodimer made of 45kD alpha and 145kD beta subunits. The alpha subunit and the amino-terminal region of beta-subunit form the extracellular domain. The remainder of the beta-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met (c-Met) with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase and is critical for all of its known biological functions. Phosphorylation of Tyr1234/1235 in the Met kinase domain is critical to kinase activation. Phosphorylation of Tyr1349 in the Met (c-Met) cytoplasmic domain provides a direct binding site for Gab1. Altered Met (c-Met) levels and/or tyrosine kinase activities were found in different tumors, especially in renal, colon and breast cancers. Thus, Met (c-Met) is an attractive therapeutic target and cancer diagnostic.
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab14570 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 2 µg/ml. Ab 14570 detects Met (c-Met) in mouse liver membrane fractions using a goat anti-rabbit secondary antibody conjugated to HRP and a chemiluminescence detection system. The antibody recognises a doublet at 170 and 140kDa as well as a non-specific protein at ~45kDa
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
- Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
- Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
- DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Cellular localizationMembrane.
- AUTS9 antibodyc met antibodycmet antibody
- D249 antibodyHepatocyte growth factor receptor antibodyHepatocyte growth factor receptor Precursor antibodyHGF antibodyHGF receptor antibodyHGF SF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyRenal cell carcinoma papillary 2 gene antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody
References for Anti-Met (c-Met) antibody (ab14570)
This product has been referenced in:
- Fan S et al. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 21:10-24 (2010). IP . Read more (PubMed: 19823077) »
- Fan S et al. Role of Src Signal Transduction Pathways in Scatter Factor-mediated Cellular Protection. J Biol Chem 284:7561-77 (2009). IP ; Human . Read more (PubMed: 19047046) »